Ethnopharmacological activity of Hedera nepalensis K. Koch extracts and lupeol against alloxan-induced type I diabetes

Authors

  • Waleed Javed Hashmi Quaid-i-Azam University, Islamabad, Faculty of Biological Sciences, Department of Biochemistry
  • Hammad Ismail University of Gujrat, Department of Biochemistry and Biotechnology
  • Laila Jafri Quaid-i-Azam University, Faculty of Biological Sciences, Department of Biochemistry
  • Bushra Mirza Quaid-i-Azam University, Faculty of Biological Sciences, Department of Biochemistry https://orcid.org/0000-0002-4134-6636

DOI:

https://doi.org/10.1590/s2175-97902019000318406

Keywords:

Antioxidant, Amylase, Diabetes mellitus, Insulin, Hedera nepalensis, Lupeol

Abstract

In this study, we investigated the protective effects of Hedera nepalensis crude extract, its fractions and lupeol in alloxan-induced diabetic rats. Lupeol and n-hexane (HNN) fraction significantly reduced the blood glucose level by increasing insulin level in time dependent manner, and also significantly increased amylase and lipase activity in diabetic rats. Elevated levels of alanine transaminases (ALT), aspartate transaminases (AST), thiobarbituric acid reactive substances (TBARS), nitrite, hydrogen peroxide (H2 O2 ), total bilirubin and total protein in blood serum were efficiently restored to normal levels. Suppressed enzymatic activity of catalase (CAT), superoxide dismutase (SOD), reduced glutathione (GSH) and peroxidase (POD) were also restored to their normal levels. Kidney functions were also restored to normal level after treatment with HNN and lupeol. HNN fraction and lupeol of H. nepalensis prevented oxidative stress in alloxan-induced diabetic rats. This study signifies the importance of H. nepalensis and lupeol in ameliorating diabetes by inducing insulin secretion in diabetic model rats.

Downloads

Download data is not yet available.

Downloads

Published

2020-12-09

Issue

Section

Article

How to Cite

Ethnopharmacological activity of Hedera nepalensis K. Koch extracts and lupeol against alloxan-induced type I diabetes. (2020). Brazilian Journal of Pharmaceutical Sciences, 56, e18406. https://doi.org/10.1590/s2175-97902019000318406